Nicorandil ER is under clinical development by Auxilius Pharma and currently in Phase I for Chronic Stable Angina. According to GlobalData, Phase I drugs for Chronic Stable Angina have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nicorandil ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nicorandil ER overview

Nicorandil is under development for the treatment of chronic stable angina. It is administered through oral route in the form of extended release capsule. It is a ATP sensitive inward rectifier potassium channel 1 activator.

Auxilius Pharma overview

Auxilius Pharma is a specialty pharmaceutical company focused on research and development of value-added medications for the treatment of cardiovascular diseases. The company is headquartered in Boston, Massachusetts, the US.

For a complete picture of Nicorandil ER’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.